Arvinas (NASDAQ:ARVN) Trading 0.6% Higher

Shares of Arvinas Inc (NASDAQ:ARVN) traded up 0.6% on Friday . The company traded as high as $25.53 and last traded at $25.47, 5,062 shares changed hands during mid-day trading. A decline of 99% from the average session volume of 364,888 shares. The stock had previously closed at $25.33.

Several equities research analysts have recently commented on the company. BMO Capital Markets assumed coverage on Arvinas in a report on Thursday, September 12th. They set an “outperform” rating and a $34.00 price objective for the company. Cantor Fitzgerald assumed coverage on Arvinas in a report on Monday, August 5th. They set an “overweight” rating and a $42.00 price objective for the company. Goldman Sachs Group upgraded Arvinas from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $23.00 to $38.00 in a report on Thursday, October 24th. Zacks Investment Research cut Arvinas from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Finally, Wedbush started coverage on Arvinas in a research report on Tuesday, September 24th. They set an “outperform” rating and a $38.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $32.00.

The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.79 and a current ratio of 6.79. The company has a market capitalization of $756.65 million, a P/E ratio of -1.00 and a beta of 2.13. The business has a 50 day moving average of $20.32 and a 200-day moving average of $22.49.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Monday, November 4th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.67. Arvinas had a negative return on equity of 31.57% and a negative net margin of 157.34%. The company had revenue of $30.05 million for the quarter, compared to analyst estimates of $11.42 million. As a group, equities analysts forecast that Arvinas Inc will post -1.94 EPS for the current fiscal year.

In related news, insider Ian Taylor sold 10,000 shares of the business’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $21.86, for a total transaction of $218,600.00. Insiders own 31.77% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new stake in shares of Arvinas during the 3rd quarter valued at $47,000. Chicago Equity Partners LLC bought a new position in Arvinas in the 3rd quarter worth about $675,000. Strs Ohio increased its stake in Arvinas by 276.2% in the 3rd quarter. Strs Ohio now owns 7,900 shares of the company’s stock worth $170,000 after acquiring an additional 5,800 shares during the last quarter. Nuveen Asset Management LLC bought a new position in Arvinas in the 2nd quarter worth about $4,834,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Arvinas in the 2nd quarter worth about $557,000. Institutional investors own 46.76% of the company’s stock.

About Arvinas (NASDAQ:ARVN)

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

Recommended Story: What is the Stochastic Momentum Index (SMI)?

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.